The Limited Times

Now you can see non-English news...

A Sanofi alumnus joins an AI unicorn

2022-10-04T14:56:38.261Z

Alban de la Sablière, a former investment banker, made his first deals in pharma in the early 2000s. It's a great catch for Owkin. The artificial intelligence unicorn applied to health debauchery at Sanofi. After six years in the house, Alban de La Sablière became director of business development for the young Franco-American company. For this former investment banker (Morgan Stanley), who made his first deals in pharma - including Sanofi-Aventis - in the early 2000s, it was a fairly "irresistibl



It's a great catch for Owkin.

The artificial intelligence unicorn applied to health debauchery at Sanofi.

After six years in the house, Alban de La Sablière became director of business development for the young Franco-American company.

For this former investment banker (Morgan Stanley), who made his first deals in pharma - including Sanofi-Aventis - in the early 2000s, it was a fairly

"irresistible"

call .

"The convergence between artificial intelligence, the wealth of available data and advances in biology will revolutionize the sector,

" he says.

It is rare to have a company that combines such a level in these areas.”

On the lookout for opportunities

The 40-year-old, who led Sanofi's international partnerships, is not arriving in uncharted territory.

It was his team that piloted the agreement between Owkin and Sanofi, sealed last year, around R&D programs in four forms of cancer.

The French laboratory, which injected 180 million euros, became a shareholder…

This article is for subscribers only.

You have 63% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

I ENJOY IT

Already subscribed?

Login

Source: lefigaro

All business articles on 2022-10-04

You may like

Business 2022-10-04T14:56:38.261Z
Business 2022-08-17T12:06:08.564Z

Trends 24h

Latest

© Communities 2019 - Privacy